VYNE Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
VYNE Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2015 to 2023.
  • VYNE Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$9.41M, a 6.48% increase year-over-year.
  • VYNE Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$28.4M, a 19% increase year-over-year.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$28.5M, a 22.6% decline from 2022.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$23.2M, a 68.3% increase from 2021.
  • VYNE Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$73.3M, a 71.3% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$28.5M -$5.24M -22.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-01
2022 -$23.2M +$50.1M +68.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-01
2021 -$73.3M +$182M +71.3% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-14
2020 -$256M -$160M -169% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$95.2M -$21M -28.3% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-04
2018 -$74.2M -$45.1M -155% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-04
2017 -$29.1M -$15M -107% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
2016 -$14.1M -$9.46M -205% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$4.61M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.